Welcome to 4SC

4SC discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies.

4SC AG is listed on the Frankfurt Stock Exchange (Prime Standard: VSC/ISIN DE0005753818), Germany.

21 May 2013

Press Release: 4SC's partner Yakult Honsha starts clinical Phase I/II study with cancer compound resminostat in liver cancer in Japan

Press Release 4SC's partner Yakult Honsha starts clinical Phase I/II study with cancer compound resminostat in liver cancer (HCC) in Japan - Phase I/II study to investigate...

Vidofludimus meets 1^ary endpoint in IBD

4SC’s lead compound in autoimmune diseases generates a response rate of 88.5% for the treatment of patients with Crohn's disease and ulcerative colitis... more

Resminostat: best-in-class in 2^nd line HCC

Resminostat: 8.0 months Overall Survival in Phase II SHELTER trial; "best-in-class" results in 2nd-line liver cancer (HCC) treatment: Press Release, ILCA 2012 Presentation

Learn more about 4SC